Study: Targeted therapy benefits patients with early stage lung cancer

Yale Cancer Center researchers have found that treatment with osimertinib following surgery significantly improves disease-free survival for some patients.
Source: Yale Science and Health News - Category: Universities & Medical Training Source Type: news